Has Eurotransplant Fulfilled Its Promise?

  • J. J. Van Rood


Everyone fortunate enough to have been involved in scientific research knows the excitement of obtaining a new finding or conducting an experiment that opens new vistas for further developments and possible applications. Enjoyment of life is at its peak when such excitement can be shared, preferably by a small group of scientists interested in the same topics. Nowadays there are many meetings for the exchange of research findings, but in the late 1960s when Walter Brendel began the tradition of the Round Table Symposia on Applied Immunology, this was certainly not the case. It was at these meetings that we presented our data on skin transplants and HLA matching data [1], the discovery of the DR serology [2, 3] and the impact of this on renal transplantation [4], CML nonresponsiveness developing posttransplantation [5], Ir genes in transplantation [6], and numerous other such findings. Much of what we presented dealt with the application of “basic” immunogenetics to “applied” clinical renal transplantation, most of this in the context of the Eurotransplant foundation which was initiated enthusiastically at the same time as the Round Table Symposia began [7].


Graft Survival Renal Allograft Transplant Proc Renal Allograft Survival Apply Immunology 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jonker M, Hoogeboom J, van Leeuwen A, Koch CT, Blussé van Oud Alblas A, Persijn GG, Frederiks E, van Rood JJ (1979) Experimental skin grafting in man. Transplant Proc XI: 607–610Google Scholar
  2. 2.
    Van Leeuwen A, Schuit HRE, van Rood JJ (1973) Typing for MLC (LD). II. The selection of non-stimulator cells by MLC inhibition tests using SD-identical stimulator cells (MISIS) and fluorescence antibody studies. Transplant Proc 5: 1539–1542PubMedGoogle Scholar
  3. 3.
    Van Rood JJ, van Leeuwen A, Keuning JJ, Blussé van Oud Alblas A (1975) The serological recognition of the human MLC determinants using a modified cytotoxicity technique. Tissue Antigens 5: 73–79Google Scholar
  4. 4.
    Persijn GG, Gabb BW, van Leeuwen A, Nagtegaal A, Hoogeboom J, van Rood JJ (1978) Matching for HLA antigens of A, B and DR loci in renal transplantation by Eurotransplant. Lancet 1: 1278–1281PubMedCrossRefGoogle Scholar
  5. 5.
    Goulmy E, Persijn GG, Blokland E, D’Amaro J, van Rood JJ (1981) CML studies in renal allograft recipients. Transplantation 31: 210–217PubMedCrossRefGoogle Scholar
  6. 6.
    Hendriks GFJ, D’Amaro J, Persijn GG, Schreuder GMTh, Lansbergen Q, Cohen B, van Rood JJ (1983) Excellent renal allograft prognosis with DRw6 positive donors in the face of HLA-DR mismatches. Lancet 11: 187–189CrossRefGoogle Scholar
  7. 7.
    Van Rood JJ (1967) A proposal for international cooperation in organ transplantation: Eurotransplant. In: Curtoni ES et al. (eds) Histocompatibility Testing 1967. Williams and Wilkins, Baltimore, pp. 451–458Google Scholar
  8. 8.
    Van Hooff JP, van Leeuwen A, Paul LC, Leunissen KML, Lecomte C, D’Amaro J, Cohen B, Alexandre GRJ, van Rood JJ (1985) The influence of matching for broadly reacting antigens on long-term kidney graft survival. Transplant Proc 22: 2205–2206Google Scholar
  9. 9.
    Birkeland SA (1983) Malignant tumours in renal transplant patients. Cancer 51: 1571–1575PubMedCrossRefGoogle Scholar
  10. 10.
    Van Rood JJ (1987) Prospective HLA typing is helpful in cadaveric renal transplantation. Transplant Proc XIX: 139–143Google Scholar

Copyright information

© Springer Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • J. J. Van Rood

There are no affiliations available

Personalised recommendations